ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMDespesas comerciais, gerais e administrativas16.18 M16.98 M14.95 M14.15 M15.43 M15.07 M59.6 MPesquisa e desenvolvimento37.06 M35.74 M34.45 M35.58 M31.23 M34.46 M135.72 MLucro operacional-22.22 M-25.61 M-674 K-22.11 M-44.15 M-47.12 M-114.05 MLucro não operacional, total344 K49 K-621 K315 K-302 K120 K-488 KDespesa com juros, líquida de juros capitalizados—————26 K—Receitas não operacionais, líquidas das despesas com juros597 K-2 000-613 K289 K-284 K94 K-514 KReceitas/despesas incomuns-253 K51 K-8 00026 K-18 K——Lucro antes dos impostos-17.79 M-22.14 M2.13 M-18.27 M-41.48 M-46.35 M-103.97 MParticipação no lucro———————Impostos5.71 M496 K-186 K1.34 M-270 K-2.19 M-1.31 MParticipação de minoritários———————Outras receitas/despesas após impostos———————Lucro líquido antes das operações descontinuadas-23.51 M-22.64 M2.32 M-19.6 M-41.21 M-44.16 M-102.66 MOperações descontinuadas———————Lucro líquido-23.51 M-22.64 M2.32 M-19.6 M-41.21 M-44.16 M-102.66 MAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas-23.05 M-22.81 M2.32 M-19.77 M-41.06 M-44.22 M-102.73 MLucro básico por ação-0.32-0.30.03-0.26-0.55-0.59-1.37Lucro diluído por ação-0.32-0.30.03-0.26-0.55-0.59-1.37Número médio de ações básicas75.85 M75.17 M75.34 M75.77 M75.4 M74.67 M—Ações diluídas75.88 M75.23 M77.38 M75.78 M75.41 M74.69 M—EBITDA-16.72 M-23.02 M3.43 M-17.33 M-39.2 M-45.19 M-98.28 MEBIT-22.22 M-25.61 M-674 K-22.11 M-44.15 M-47.12 M-114.05 MCusto da receita———————Outros componentes do custo———————Amortização e depreciação (fluxo de caixa)5.49 M2.6 M4.11 M4.78 M4.95 M1.93 M15.77 M
Zymeworks Inc. - Common Stock
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.